会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • ELASTIC BIOPOLYMER AND USE AS A TISSUE ADHESIVE
    • 弹性生物反应器和用作组织粘合剂
    • WO2016022807A1
    • 2016-02-11
    • PCT/US2015/044022
    • 2015-08-06
    • THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    • KHADEMHOSSEINI, AliANNABI, NasimASSMANN, Alexander
    • A61L24/04
    • A61L24/104A61K31/137A61L24/001A61L24/0015A61L24/0031A61L2300/104A61L2300/404A61L2300/418A61L2400/04
    • The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response. Advantageously, the tissue adhesives of the present invention are low cost and easy to produce, making them a promising substance to be used as a sealant for fluid leakages in soft tissue, as well as an easily tunable platform to further optimize the adhesive characteristics.
    • 本发明提供了一种改进的组织粘合剂来修复软组织中的缺陷。 根据ASTM标准测试,本发明的交联甲基丙烯酰基取代的明胶水凝胶(GelSEAL)显示出优于临床使用的纤维蛋白和聚(乙二醇)的粘合性质,即伤口闭合强度,抗剪切性和爆裂压力, 的胶水。 大鼠的慢性体内实验证明,GelSEAL能有效地密封大的肺部泄漏,无需额外的缝线或缝钉,与纤维蛋白和聚(乙二醇)胶相比具有改善的性能。 此外,皮下植入大鼠显示出GelSEAL的高生物相容性,这是由低炎症宿主反应证明的。 有利地,本发明的组织粘合剂成本低且易于生产,使得它们成为用作软组织中的流体泄漏的密封剂的有希望的物质,以及用于进一步优化粘合剂特性的容易调节的平台。
    • 8. 发明申请
    • METHOD AND SYSTEM FOR GENERATING SPATIALLY AND TEMPORALLY CONTROLLABLE CONCENTRATION GRADIENTS
    • 用于产生空间和时间可控浓度梯度的方法和系统
    • WO2010057078A2
    • 2010-05-20
    • PCT/US2009/064555
    • 2009-11-16
    • THE BRIGHAM AND WOMEN'S HOSPITAL, INC.KHADEMHOSSEINI, AliDU, Yanan
    • KHADEMHOSSEINI, AliDU, Yanan
    • G01N35/08G01N33/48C12Q1/00
    • G01N30/34B01L3/50273B01L3/502776B01L2300/0816G01N1/405G01N2001/4088G01N2030/342Y10T436/2575G01N30/6095
    • The ability to rapidly generate concentration gradients of diffusible molecules has important applications in many chemical and biological studies. The present invention is directed to methods and systems for generating spatially and temporally controllable concentration gradients of molecules (i.e. proteins or toxins) in a portable microfluidic device. The formation of the concentration gradients can be initiated by an induced forward flow and further optimized during an induced backward flow. The forward and backward flows can be either passively induced and/or actively pumped. The centimeter-length gradients along the microfluidic channel can be spatially and temporally controlled by the backward flow. The gradient profile was stabilized by stopping the flow. In one example, a stabilized concentration gradient of a cardiac toxin, Alpha-cypermethrin, generated according to the invention was used to test the response of HL-1 cardiac cells in the microfluidic device, which correlated with toxicity data obtained from multi-well plates. The invention can be useful for biological and chemical processes that require rapid generation of concentration gradients in a portable microfluidic device.
    • 快速产生扩散分子的浓度梯度的能力在许多化学和生物学研究中具有重要的应用。 本发明涉及用于在便携式微流体装置中产生分子(即蛋白质或毒素)的空间和时间可控浓度梯度的方法和系统。 浓度梯度的形成可以通过诱导的正向流引发并且在诱导的逆流期间进一步优化。 前向和后向流可以被动地被诱导和/或被主动泵送。 沿着微流体通道的厘米长度梯度可以由反向流动在空间和时间上控制。 通过停止流动来稳定梯度分布。 在一个实例中,使用根据本发明产生的心脏毒素α-氯氰菊酯的稳定化浓度梯度来测试微流体装置中HL-1心脏细胞的反应,其与从多孔板获得的毒性数据相关 。 本发明可用于需要在便携式微流体装置中快速产生浓度梯度的生物和化学过程。